Osteoscreen, Inc.

Zymogenetics, Inc.

Other

University of Texas System

Rhone-poulenc Rorer Pharmaceuticals Inc.

Osteosa Inc.

Xenotech, L.l.c.

University of California

Dartmouth College

Osteoscreen Ip, LLC

Osteosa Liquidation Trust

Gregory R Mundy

Nand Baindur

Kirk G Robbins

Charles R Petrie

Mark W Orme

I Ross Garrett

Maria Kontoyianni

Jorge Gianny Rossini

Virender M Labroo

Patricia A McKernan

Robert R West

Scott M Harris

Theresa Martinez

Toshiyuki Yoneda

Shirley R Gasper

Laurence H Hurley

Wilson H Burgess

Sean Michael Kerwin

Elzbieta Izbicka

Michael C Jaye

Colin R Dunstan

G Rossini

Gordon W Gribble

Michael B Sporn

Tadashi Honda

Bob M Moore, Ii

Karen T Liby

Clarence C Morse

Gloria Gutierrez

Gregg R Crumley

A Hari Reddi

Wolfgang E Gallwitz

Nandini Ghosh-Choudhury

Jian Q Feng

Stephen E Harris

Timothy R Arnett

Massimo Sabatini

Ian R Garrett

Gloria E Gutierrez

Toshiyuka Yoneda

Ross Garrett

Theresa A Guise

Takahiro Niikura

Mark R DeLuca

Mark V Craig

The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.

Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth

Antagonists of &#x3b1;4 integrin/&#x3b1;4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their &#x3b1;4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Antagonists of alpha 4 integrin/alpha 4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha 4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

The topical administration of statins for the treatment of bone disorders is disclosed.

Topical administration of statins for treatment of bone disorders

This inventions relates to compounds that inhibit the activity of the proteasome and both promotes hair growth and stimulates the production of hair follicles. The compounds provided herein are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

Inhibitors of proteasomal activity for stimulating hair growth

The present invention relates to compounds that inhibit the activity of the proteasome or the production of proteasomal proteins and promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation, in subject where this is desirable.

Inhibitors of proteasomal activity for stimulating bone growth

Compounds that inhibit the activity of NF-&#x3ba;B or inhibit the activity of the proteasome or both promote bone formation and hair growth and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyrdidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation; they also stimulate the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

The present invention relates to compounds that inhibit the activity of the proteasome or the productions of proteasomal proteins and promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgey, and post-dental implantation, in subject where this is desirable.

The present invention relates to compounds that inhibit the activity of the proteasome or the production of proteasomal proteins and promote the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

The present invention relates to methods for stimulating osteoblast proliferation and methods for selecting pharmacologically active compounds useful for stimulating osteoblast proliferation.

Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants

The present invention relates to compounds that inhibit the activity of the proteasome or the production of proteasomal proteins and promote hair growth and the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

Inhibitors of proteasomal activity for stimulating bone and hair growth

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or &ldquo;linker&rdquo; defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 &angst;, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

Compositions and methods for treating bone deficit conditions

Isoprenoid pathway inhibitors for stimulating bone growth

The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-&kgr;B. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-&kgr;B provides a useful means to identify agents to treat myeloma bone disease.

Treatment of myeloma bone disease with proteasomal and NF-&kgr;B activity inhibitors

Compounds that inhibit the activity of NF-&kgr;B or inhibit the activity of the proteasome or both promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

Inhibitors of proteasomal activity and production for stimulating bone growth

Growing community of inventors

San Antonio, TX, United States of America

Gregory R Mundy